ALK and anaplastic large cell lymphoma: Here, we examined the possible on-target effects of crizotinib as TKI specifically inhibiting ALK, using ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) as a model, where ALK is expressed and activated following a chromosomal translocation (t(2;5)) leading to the fusion with nucleophosmin 1 (NPM1) [36].